Recent Updates

March 2019

Cilique (ethinylestradiol 35micrograms/ norgestimate 250micrograms) tablets have been added to the formulary as a green (first line) option for hormonal contraception. Click here for more information.

  • Cilest (ethinylestradiol 35micrograms/ norgestimate 250micrograms) tablets have been discontinued by the manufacturer and have been removed from the formulary

Cilodex (ciprofloxacin 3mg/ml & dexamethasone 1mg/ml) ear drops, suspension has been added to formulary as a blue (second line) option for acute otitis externa (AOE) in adults and children over 1 year of age. Click here for more information.

DEKAs Plus (liquid, chewable tablets, and softgels) and DEKAs Essential capsules have been added to the formulary as amber (specialist input) options for the dietary management of cystic fibrosis patients. Click here for more information.

Paravit-CF liquid has been added to the formulary as amber (specialist input) options for the dietary management of cystic fibrosis in babies and patients with swallowing difficulties. Click here for more information.

Lyme disease: Formulary guidance has been revised and updated. The updated guidance provides more detail including specific antibiotic recommendations depending on the patient's age and presenting symptoms. Please see the formulary for further guidance.

Management of gout: Formulary guidance has been revised and updated. Please see the formulary for further guidance.

Dexamfetamine drug entry has been updated to support and guide prescribers on the safe and effective use of the medication. Please see the formulary for further guidance.

January 2019

Cholurso® has been removed as the preferred brand of ursodeoxycholic acid 250mg tablets; generic prescribing is now recommended. Click here for more information.

Emollients: The choice of formulary emollient preparations has been updated with supporting guidance to aid prescribers. Click here for more information.

Prolongation of the QT interval: New guidance relating to drugs that prolong the QT interval has been developed and added to the cardiovascular chapter. Please see the formulary for further guidance.

Unipolar depression: NICE and Devon Partnership NHS Trust (DPT) prescribing guidelines have been used to revise and update formulary guidance. Please see the formulary for further guidance.

Palliative care opioid equivalency table has been updated and a link to the document hosted on the Rowcroft Hospice website has been added to the formulary.

November 2018

Acidex advance 1g/200mg in 10ml oral suspension has been added to formulary for reducing symptoms of laryngopharyngeal reflux. Click here for more information.

Kyleena 19.5mg intrauterine system has been added to formulary for contraception in women, licensed for up to 5 years. Click here for more information.

Ciclosporin 1mg/1ml (Ikervis) single use eye drops have been reclassified from red to amber (specialist input) following consultation with local specialists. Click here for more information.

Following completion of the EMA safety review, ulipristal acetate 5mg (Esmya) tablets have been reclassified from amber to red (hospital only). Click here for more information.

Acute sinusitis: Following publication of NICE NG79 Sinusitis (acute): antimicrobial prescribing (October 2017)., formulary guidance has been revised and updated. Please see the formulary for further guidance.

Infantile colic: Using NICE CKS (2017): Colic – infantile and NICE clinical guideline CG37 (2015): Postnatal care up to 8 weeks after birth, local guidance has been updated and refreshed to provide easily accessible information to primary care prescribers. Please see the formulary for further guidance.

Anal irrigation systems: New guidance has been added to the formulary to offer advice and product suggestions recommended by local specialists. Please see the formulary for further guidance.

Anal inserts: New guidance has been added to the formulary to offer advice and product suggestions recommended by local specialists. Please see the formulary for further guidance.

Commissioning Policy: The routine commissioning of Tresiba® (insulin degludec) is accepted in Devon for the treatment of patients with type 1 diabetes who meet specific criteria (See Commissioning Policy for more information). Tresiba has been added to the formulary as an amber (specialist input) option in line with the policy. Click here for more information

Commissioning Policy: The routine commissioning of Tresiba® (insulin degludec) in Devon for the treatment of type 2 diabetes is unchanged and is not accepted (See Commissioning Policy for more information)

Commissioning Policy: The routine commissioning of Trelegy® Ellipta® (combination of fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate) is accepted in Devon for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) (See Commissioning Policy for more details). Trelegy Ellipta has been added in the formulary as a green (first line) option in line with the policy. Click here for more information

Consideration given to: West Devon shared care / Specialised Medicines Service (SMS) prescribing guidelines for DMARDs for rheumatological conditions have been updated and combined. The new guidelines provide guidance on the safe use and monitoring of the following medicines, when prescribed as part of shared care with rheumatology specialists at University Hospitals Plymouth NHS Trust:

  • Azathioprine
  • Ciclosporin
  • Leflunomide
  • Methotrexate
  • Mycophenolate mofetil
  • Sodium aurothiomalate (gold)
  • Sulfasalazine

This update includes changes to the monitoring requirements for some medicines; please refer to the guidelines for more details. The guidelines are available on the NHS Devon CCG website here, and are linked to from the relevant pages of the formulary.

 

Home > Formulary > Updates > Recent Updates

 

  • First line
  • Second line
  • Specialist
  • Hospital